Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GSK343 |
| Synonyms | |
| Therapy Description |
GSK343 is an inhibitor of EZH2, which decreases tri-methylation of H3K27, potentially resulting in decreased growth and increased apoptosis of tumor cells (PMID: 23759589, PMID: 31791385). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK343 | GSK-343|GSK 343 | EZH2 inhibitor 20 | GSK343 is an inhibitor of EZH2, which decreases tri-methylation of H3K27, potentially resulting in decreased growth and increased apoptosis of tumor cells (PMID: 23759589, PMID: 31791385). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|